Document:

EXECUTION
VERSION

 

AMENDMENT
TO

ASSET
PURCHASE AGREEMENT

 

This
Amendment to Asset Purchase Agreement (this “Amendment”), dated as of January 8, 2019, is entered into by and
among Regenerative Medicine Solutions LLC, a Delaware limited liability company (“RMS”), RMS Shareholder, LLC,
a Delaware limited liability company and the sole member of RMS (“RMS Shareholder”), Lung Institute LLC, a
Delaware limited liability company (“Lung Institute”), RMS Lung Institute Management LLC, a Delaware limited
liability company (“RMS Management”), Cognitive Health Institute Tampa, LLC, a Delaware limited liability company
(“CHIT” and, together with Lung Institute and RMS Management, the “Operating Subsidiaries”),
Medovex Corp., a Nevada corporation (“Medovex”) and RMS Acquisition Corp., a Nevada corporation (“Buyer”).
For purposes of this Agreement, “Seller” shall mean individually and collectively RMS and the Operating Subsidiaries,
together with any other entity selling or assigning assets of the Seller Business pursuant to this Agreement. The Buyer, Seller,
RMS Shareholder and Medovex are sometimes referred to collectively as the “Parties.”

 

RECITALS

 

WHEREAS,
the Parties previously entered into that certain Asset Purchase Agreement, dated October 15, 2018 (the “Agreement”);
and

 

WHEREAS,
the Parties desire to amend the Agreement as provided in this Amendment.

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements set forth in this Amendment, and for other good and valuable
consideration, the receipt and sufficiency of which are acknowledged, the Parties agree as follows:

 

1.
Terms. If a term is capitalized in this Amendment but not defined, then it has the meaning given to it in the Agreement.

 

2.
Amendments. The Agreement is amended as follows:

 

(a)
The fourth paragraph of the recitals is deleted in its entirety and the following is substituted in its place:

 

“WHEREAS,
Seller, Buyer, and Medovex intend that (i) the transaction contemplated by this Agreement be treated as a tax-deferred exchange
pursuant to the provisions of Section 368(a)(1)(C) and 368(a)(2)(C) of the Internal Revenue Code of 1986, as amended (the “Code”),
on the terms and conditions set forth in this Agreement, and (ii) that this Agreement constitute a “plan of reorganization”
within the meaning of Treasury Regulation Section 1.368-2(g);”

 

(b)
Schedule 2.01(b) is deleted in its entirety, and the Schedule 2.01(b) attached to this Amendment is substituted in its place.

 

(c)
Section 2.01(j) is deleted in its entirety and the following is substituted in its place:

 

    	 

    	 

    

 

“(j)
except as provided in Section 2.02(i), all insurance benefits, including rights and proceeds, arising from or relating to the
Seller Business, the Purchased Assets or the Assumed Liabilities;”

 

(d)
Section 2.03(a) is deleted in its entirety and the following is substituted in its place:

 

“(a)
the trade accounts payable and credit card liabilities of Seller to third parties in connection with the Seller Business that
remain unpaid and are not more than one hundred twenty days (120) past due as of the Closing Date and which are set forth on Schedule
2.03(a) attached hereto; and”

 

(e)
Schedule 2.03(a) is deleted in its entirety, and the Schedule 2.03(a) attached to this Amendment is substituted in its place.

 

(f)
Section 2.05(a), Section 2.05(a)(i), and Section 2.05(a)(i)(A) are deleted in their entirety and the following are substituted
in their place:

 

“(a)
Medovex will issue to RMS Shareholder and Buyer will deliver to Seller at the Closing that number of shares of Series C Preferred
Stock (defined below, such Series C Preferred Stock, as adjusted pursuant to Section 2.05(f) being referred to as the “Exchange
Shares”) which shall represent the right to convert into and acquire without further consideration, the excess of:

 

(i)
fifty-five percent (55%) of the outstanding Common Stock (defined below) of Medovex on the Closing Date (inclusive of all Exchange
Shares):

 

(A)
including for purposes of calculating the outstanding shares of Common Stock on the Closing Date (1) all shares of Common Stock
that are reserved for issuance upon conversion of the outstanding Series A Preferred Stock, the Series B Preferred Stock, and
the Series C Preferred Stock (other than the Exchange Shares), (2) all shares of Common Stock that are reserved for issuance upon
conversion of the 12% Senior Secured Convertible Notes, and (3) all shares of Common Stock that are reserved for issuance upon
conversion of the 12% Convertible Notes that will automatically convert on the Closing Date.”

 

(g)
Section 2.05(f)(iv) is deleted in its entirety and the following is substituted in its place:

 

“(iv)
Notwithstanding the foregoing provisions of this Section 2.05(f), Seller shall not be entitled to receive, and Buyer shall not
be obligated to issue to Seller, any Additional Exchange Shares following such time as an aggregate of five million six hundred
fifty thousand dollars ($5,650,000) of New Securities and shares of capital stock sold pursuant to Section 7.03(d) (on a fully
diluted basis) have been sold by Medovex or a Medovex Member and included in the calculation of Exchange Shares or Additional
Exchange Shares. For purposes of clarity, it is the intent of Seller and Buyer that Seller’s Exchange Shares shall not be
diluted by the issuance and sale of New Securities, including shares of capital stock sold pursuant to Section 7.03(d) (calculated
on a fully diluted basis), until five million six hundred fifty thousand dollars ($5,650,000) of New Securities and shares of
capital stock sold pursuant to Section 7.03(d) have been sold by Medovex or a Medovex Member. Thereafter, Seller and the shareholders
of Medovex shall dilute pro rata based upon their respective ownership percentages.

 

    	 

    	 

    

 

(h)
Schedule 2.05 is deleted in its entirety, and the Schedule 2.05 attached to this Amendment is substituted in its place.

 

(i) Section
3.01 is deleted in its entirety and the following is substituted in its place:

 

“Section
3.01 Closing. Subject to the terms and conditions of this Agreement, the consummation of the transactions contemplated by
this Agreement (the “Closing”) shall take place at a location and time mutually agreed upon by Buyer and RMS
on the second Business Day after all of the conditions to Closing set forth in ARTICLE VII are either satisfied or waived (other
than conditions which, by their nature, are to be satisfied on the Closing Date). The date on which the Closing is to occur is
herein referred to as the “Closing Date”. The Closing shall be effective at 11:59 pm on the Closing Date.”

 

(j)
Section 3.02(b) is amended to add a new clause (vi) which shall read as follows:

 

“(vi)
evidence that Medovex has appropriate policies of directors’ and officers’ liability insurance.”

 

(k) Section
3.03 is deleted in its entirety and the following is substituted in its place: 

 

“Section
3.03 Liquidation. Prior to but in conjunction with the Closing, RMS agrees to adopt a plan of liquidation and distribution
that will be effectuated upon the complete resolution of the Tampa Litigation, and pursuant to which, prior to the resolution
of the Tampa Litigation, the board of managers of RMS agrees (a) not to acquire any assets or undertake any operations or activities
other than as necessitated by the Tampa Litigation, (b) to distribute to RMS Shareholder the Exchange Shares, and (c) to dissolve
its corporate existence and liquidate its affairs as soon as practical following the resolution of the Tampa Litigation. RMS shall
liquidate in accordance with the plan of liquidation and distribution to be adopted before the Closing Date by the board of directors
of RMS (a copy of which shall be supplied to Buyer’s counsel before the Closing Date).”

 

(l)
Section 4.03, Section 4.07(a), Section 4.10(a), Section 4.14, and Section 4.18(a) of the Disclosure Schedules shall be replaced
in their entirety with Section 4.03, Section 4.07(a), Section 4.10(a), Section 4.14, and Section 4.18(a) attached to this Amendment.

 

    	 

    	 

    

 

(m)
Section 6.04(b)(i) is deleted in its entirety and the following is substituted in its place:

 

“(i)
Until such time as all of the Additional Exchange Shares have been issued and delivered to RMS, Medovex may issue and sell only
its Common Stock, warrants to acquire its Common Stock, Series C Preferred Stock, warrants to acquire its Series C Preferred Stock,
or unsecured promissory notes that convert automatically into Common Stock upon the Closing (but not any other series of its capital
stock, or any option, warrant, security, or other right to acquire or convertible into any other series of capital stock of Medovex);
and”

 

(n)
Section 6.05(b) is deleted in its entirety and the following substituted in its place:

 

“(b)
Seller shall be solely responsible, and Buyer shall have no obligations whatsoever for, any compensation or other amounts payable
to any current or former employee, officer, director, independent contractor or consultant of the Seller Business, including,
without limitation, hourly pay, commission, bonus, salary, accrued vacation, fringe, pension or profit sharing benefits or severance
pay for any period relating to the service with Seller at any time on or prior to the Closing Date and Seller shall pay all such
amounts to all entitled persons on or prior to the Closing Date; provided, however, Buyer shall be responsible for any compensation
or other amounts payable to any current or former employee, officer, director, independent contractor or consultant of the Seller
Business, including, without limitation, hourly pay, commission, bonus, or salary, for the period of January 1, 2019 through the
Closing Date, and Seller shall reimburse and indemnify Buyer for all such amounts.”

 

(o)
Section 6.11 is deleted in its entirety and the following is substituted in its place:

 

“Section
6.11 Medovex Board of Directors. Subject to the fiduciary duties of the Board of Directors of Medovex, Medovex shall take
all necessary corporate action to cause the Board of Directors of Medovex to consist of Michael Yurkowsy, Raymond Monteleone and
William Horne as of the Closing.”

 

(p)
Section 6.12 is deleted in its entirety and the following is substituted in its place:

 

“Section
6.12 Management Employment Agreement. After the Closing, subject to the approval of the Medovex Board of Directors appointed
as provided in Section 6.11, Medovex shall enter into an employment agreement with James St. Louis in form and substance satisfactory
to both Medovex and Mr. St. Louis (the “Management Employment Agreement”).”

 

    	 

    	 

    

 

(q)
Section 6.21 shall be added to Article VI and shall read as follows:

 

“Section
6.21 Post-Closing Patient Treatment. Medovex, Buyer and Seller acknowledge and agree that as of the Closing, Buyer will not
have in effect a general and professional liability insurance policy that will cover certain patients that will be transferred
from Seller or an Operating Subsidiary to Buyer. Accordingly, Medovex, Buyer and Seller agree that Seller and the Operating Subsidiaries
may continue to treat such patients following the Closing until such time as Buyer obtains a general and professional liability
insurance policy, but in no event for a period longer than ninety (90) days. All revenue generated by Seller or an Operating Subsidiary
with respect to such patients shall be paid to Buyer to reimburse it for its general, administrative, and employment-related expenses.
To the extent this provision is inconsistent with any other provision in this Agreement, the terms of this provision shall control.”

 

(r)
Sections 7.03(d) is deleted in its entirety and the following is substituted in its place:

 

“(d)
As of the Closing, Medovex shall have $1,000,000 of cash on its balance sheet (which amount shall include the $350,000 payable
to Seller, and all of which shall be treated as a credit against the $5,650,000 referenced in Section 2.05(f)(iv)).”

 

(s)
Section 7.03(e) is deleted in its entirety and the following substituted in its place:

 

“(e)
Intentionally Deleted.”

 

(t)
Section 7.03(h) is deleted in its entirety and the following substituted in its place:

 

“(h)
Medovex shall have reduced the number of its Board of Directors to no more than three members.”

 

(u)
The acknowledgment attached to this Amendment shall be signed by the Restricted Persons and added to the Agreement following the
last signature page.

 

3.
Effect; Ratification. The Agreement is amended only as set forth in this Amendment, but the Agreement shall be construed
in a manner consistent with this Amendment. Except as expressly amended by this Amendment, the Agreement remains unchanged and
in full force and effect.

 

4.
Counterparts. This Amendment may be executed in counterparts, each of which shall be deemed an original and all of such
counterparts shall constitute one and the same instrument. Facsimile and electronic signatures shall be accepted as if original.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Amendment as of this 4th day of January, 2019, to be effective as of the date
first above written.

 

	 	Regenerative
    Medicine Solutions, LLC
	 	 
	 	By:
    	/s/ James
    St. Louis 
	 	Name:
    	James
    St. Louis
	 	Title:	CEO
    and Manager
	 	 	 
	 	RMS
    Shareholder, LLC
	 	 
	 	By:	/s/
    James St. Louis 
	 	Name:	James
    St. Louis
	 	Title:	CEO
    and Manager
	 	 	 
	 	Lung
    Institute LLC
	 	 
	 	By:	/s/
    James St. Louis 
	 	Name:	James
    St. Louis
	 	Title:	CEO
    and Manager
	 	 	 
	 	RMS
    Lung Institute Management LLC
	 	 
	 	By:	/s/ James
    St. Louis
	 	Name:	James
    St. Louis
	 	Title:	CEO
    and Manager
	 	 	 
	 	Cognitive
    Health Institute Tampa, LLC
	 	 
	 	By:	/s/ James
    St. Louis
	 	Name:	James
    St. Louis
	 	Title:	CEO
    and Manager
	 	 	 
	 	Medovex
    Corp.
	 	 	 
	 	By:	/s/ Charles
    Farrahar
	 	Name:	Charles
    Farrahar
	 	Title:	Chief
    Financial Officer
	 	 	 
	 	RMS
    Acquisition Corp.
	 	 
	 	By:	/s/ Charles
    Farrahar 
	 	Name:	Charles
    Farrahar
	 	Title:	Chief
    Executive Officer

 

    	 

    	 

    

 

Schedule
2.01(b)

 

Assigned
Contracts

 

Amended
and Restated Management Services Agreement by and between Lung Institute Dallas, PLLC, a Texas professional limited liability
company (Medical Group) and RMS Dallas, LLC, a Delaware limited liability company (Manager) dated January 1, 2017.

 

Amended
and Restated Management Services Agreement by and between Lung Institute Pittsburgh, PLLC, a Pennsylvania professional limited
liability company (Medical Group) and RMS Pittsburgh, LLC, a Delaware limited liability company (Manager).

 

Management
Services Agreement by and between Lung Institute of Nashville, PLLC, a Tennessee professional limited liability company and RMS
Nashville, LLC dated October 2, 2014.

 

Management
Services Agreement by and between Lung Institute Scottsdale LLC and RMS Scottsdale, LLC dated January 9, 2015.

 

Lung
Health Institute Marketing Contract by and between Burg & Co. Marketing and Lung Health Institute dated March 28, 2017. In
effect until December 31, 2018.

 

Master
Services Agreement between Lung Health Institute, LLC and Daniel J. Edelman, Inc. dated May 9, 2018.

 

Independent
Contractor Professional Services Agreement by and between Regenerative Medicine Solutions and Russell Winwood dated March 1, 2018.

 

Lease
Agreement by and between Healthcare Realty Services Incorporated, a Tennessee corporation, as agent for HRT of Tennessee, Inc.,
a Tennessee corporation (the “Landlord”) and Regenerative Medicine Solutions, LLC dated September 10, 2014, as amended
on October 13, 2017, extending the term of the Lease.

 

Lease
Agreement by and between NPG Venture, L.P. (Landlord) and RMS Pittsburgh, LLC (Tenant) dated April 2015.

 

Standard
Form Office Lease by and between Terrance Tower Tampa, LLC (Original Landlord) and Advanced Healthcare Partners, LLC (Tenant)
dated May 7, 2013. Original Landlord assigned lease to ROC II, Fairlead Fifth Third Center, LLC (ROC II) on July 28, 2014. Assignment
of Lease by and between Tenant and Regenerative Medicine Solutions, LLC (RMS) as of May 21, 2015, whereby Tenant assigned all
interest under the Lease to RMS. First Amendment to Standard Form Office Lease by and between ROC II and RMS dated June 12, 2015,
expanding rentable square feet.

 

Lease
Agreement by and between DTR7Y, LLC (Landlord) and RMS Scottsdale, LLC (Tenant) dated January 9, 2015, as amended by that certain
First Amendment dated May 15, 2018.

 

    	 

    	 

    

 

Agreement
Regarding Membership Interest by and between Ann Sells (Miller)/MW Family Office, LLC and Regenerative Medicine Solutions, LLC
dated December 15, 2015.

 

Agreement
Regarding Membership Interest by and between Jeremy Daniel/J&SD Family Office, LLC and Regenerative Medicine Solutions, LLC
dated December 15, 2015.

 

Agreement
Regarding Membership Interest by and between James St. Louis/St. Louis Family Office, LLC and Regenerative Medicine Solutions,
LLC dated December 15, 2015.

 

Office
Lease by and between SCG/CP One Glen Lakes, LLC and RMS Dallas, LLC dated December 4, 2015.

 

Business
Associate Agreement by and between Regenerative Medicine Solutions, LLC and ZOHO Corporation dated January 4, 2016.

 

Software
License Agreement by and between Regenerative Medicine Solutions, LLC and AaNeel Infotech, LLC dated September 27, 2016.

 

Managed
Services Agreement by and between Regenerative Medicine Solutions, LLC and Offsite Technology Solutions dated December 22, 2014.

 

Service
Agreement by and between Regenerative Medicine Solutions, LLC and RingCentral, Inc. dated August 24, 2015, amended by that certain
First Amendment to Supplemental Terms of Service Agreement, as amended by that Second Amendment to Supplemental Terms of Service
Agreement.

 

    	 

    	 

    

 

Schedule
2.03(a)

 

Assumed
Liabilities

 

Accounts
Payable as of 1/2/2019:

 

 

    	 

    	 

    

 

Schedule
2.05

 

Exchange
Shares

 

	 	24,717,271	shares
    (Common Stock issued and outstanding)
	+	2,312,500	shares
    (Common Stock reserved for issuance upon conversion of the outstanding Series B Preferred Stock)
	+	1,875,000	shares
    (Common Stock reserved for issuance upon conversion of 12% Senior Convertible Notes)
	+	5,000,000	this
    number assumes $2.0M of New Securities raised at $0.40 per share 
	 	33,904,771	shares
    – existing Medovex Shareholders
	÷	0.45	Medovex
    %
	 	75,343,935	shares
	X	0.55	RMS
    %
	 	41,439,164	shares
    – RMS Shareholder, LLC (before deduction for $350,000 reserve)
	-	583,333	shares
    of Medovex Common Stock to reimburse $350,000 reserves at $0.60 per share)
	 	40,855,832	 
	-	1,083,333	shares
    of Medovex Common Stock (to reimburse $650,000 RMS payment at $0.60 per share)
	 	39,772,499	shares
    of Common Stock represented by 39,772.499 shares of Series C Preferred Stock that will be convertible into 39,772,499
    shares of Medovex Common Stock

 

Additional
Exchange Shares

 

Based
on the assumption that Medovex raises $5,650,000 of New Securities at $0.40 per share (prior to or after Closing), the Company
would issue 14,125,000 shares of Common Stock after the execution of the Asset Purchase Agreement:

 

	 	24,717,271	shares
    (Common Stock issued and outstanding prior to the issuance of New Securities)
	+	2,312,500	shares
    (Common Stock reserved for issuance upon conversion of the outstanding Series B Preferred Stock)
	+	1,875,000	shares
    (Common Stock reserved for issuance upon conversion of 12% Senior Secured Convertible Notes)
	+	14,125,000	This
    number assumes $5.65M of New Securities raised at $0.40 per share
	 	43,029,771	shares
	÷	0.45	Medovex
    %
	 	95,621,713	total
    number of shares issued and outstanding post closing;
	X	0.55	RMS
    %
	 	52,591,942	shares
    – RMS Shareholder, LLC (before deduction for $350,000 reserve)
	-	583,333	shares
    of Medovex Common Stock (to reimburse $350,000 RMS reserves at $0.60 per share)
	-	1,083,333	shares
    of Medovex Common Stock (to reimburse $650,000 RMS payment at $0.60 per share)
	 	50,925,276	shares
    of Common Stock issued to RMS Shareholder after Series C Preferred Stock is converted to Common Stock to be owned by RMS Shareholder,
    LLC;
	-	39,772,499	shares
    issued at Closing
	 	11,152,777	shares
    of Common Stock issued to RMS Shareholder, LLC as Additional Exchange Shares. If sufficient shares of Common are not yet authorized,
    then the Additional Exchange Shares will be 11,152,777 of Series C Preferred Stock.

 

Notes:

 

i)
There are presently 49.5M shares of Medovex Common Stock Authorized;

ii)
Minimum of 44,455,047 additional new shares will need to be authorized to execute this transaction;

iii)
New Securities of up to $5.65M shall dilute the 45% Medovex shareholders;

iv)
New Securities over and above $5.65M shall dilute all shareholders ratably.

 

    	 

    	 

    

 

Section
4.03

 

Required
Consents

 

First
Amendment to Management Services Agreement by and between Lung Institute Dallas, PLLC, a Texas professional limited liability
company (Medical Group) and RMS Dallas, LLC, a Delaware limited liability company (Manager).

 

Amended
and Restated Management Services Agreement by and between Lung Institute Pittsburgh, PLLC, a Pennsylvania professional limited
liability company (Medical Group) and RMS Pittsburgh, LLC, a Delaware limited liability company (Manager).

 

Master
Services Agreement between Lung Health Institute, LLC and Daniel Edelman, Inc. dated May 9, 2018. Neither party may assign this
Agreement or any rights or obligations hereunder, whether directly or indirectly, without the prior written consent of the other
party.

 

Independent
Contractor Professional Services Agreement by and between Regenerative Medicine Solutions and Russell Winwood dated March 1, 2018.
Regenerative Medicine Solutions cannot assign its rights or obligations under this Agreement without the prior written consent
of Russell Winwood.

 

Lease
Agreement by and between Healthcare Realty Services Incorporated, a Tennessee corporation, as agent for HRT of Tennessee, Inc.,
a Tennessee corporation (the “Landlord”) and Regenerative Medicine Solutions, LLC dated September 10, 2014, as amended
on October 13, 2017, extending the term of the Lease.

 

Lease
Agreement by and between NPG Venture, L.P. (Landlord) and RMS Pittsburgh, LLC (Tenant) dated April 2015. Tenant shall not, without
Landlord’s prior written consent (to be granted or denied in Landlord’s sole and absolute discretion), assign this
Lease or sublet all or any part of the Premises.

 

Standard
Form Office Lease by and between Terrance Tower Tampa, LLC (Original Landlord) and Advanced Healthcare Partners, LLC (Tenant)
dated May 7, 2013. Original Landlord assigned lease to ROC II, Fairlead Fifth Third Center, LLC (ROC II) on July 28, 2014. Assignment
of Lease by and between Tenant and Regenerative Medicine Solutions, LLC (RMS) as of May 21, 2015, whereby Tenant assigned all
interest under the Lease to RMS. First Amendment to Standard Form Office Lease by and between ROC II and RMS dated June 12, 2015,
expanding rentable square feet. RMS shall have no right to assign or sublease any portion of the Lease without consent from Advanced
Healthcare Partners, LLC and ROC II.

 

Lease
Agreement by and between DTR7Y, LLC (Landlord) and RMS Scottsdale, LLC (Tenant) dated January 9, 2015, as amended by that certain
First Amendment dated May 15, 2018.

 

Office
Lease by and between SCG/CP One Glen Lakes, LLC and RMS Dallas, LLC dated December 4, 2015.

 

Software
License Agreement by and between Regenerative Medicine Solutions, LLC and AaNeel Infotech, LLC dated September 27, 2016.

 

    	 

    	 

    

 

Section
4.07(a)

 

Material
Contracts

 

First
Amendment to Management Services Agreement by and between Lung Institute Dallas, PLLC, a Texas professional limited liability
company (Medical Group) and RMS Dallas, LLC, a Delaware limited liability company (Manager). Neither party may assign its interest
in or delegate the performance of its obligations under this Agreement to any other person without obtaining the prior written
consent of the other party.

 

Amended
and Restated Management Services Agreement by and between Lung Institute Pittsburgh, PLLC, a Pennsylvania professional limited
liability company (Medical Group) and RMS Pittsburgh, LLC, a Delaware limited liability company (Manager). Neither party may assign
its interest in or delegate the performance of its obligations under this Agreement to any other person without obtaining the
prior written consent of the other party.

 

Management
Services Agreement by and between Lung Institute of Nashville, PLLC, a Tennessee professional limited liability company and RMS
Nashville, LLC dated October 2, 2014.

 

Management
Services Agreement by and between Lung Institute Scottsdale LLC and RMS Scottsdale, LLC dated January 9, 2015.

 

Lung
Health Institute Marketing Contract by and between Burg & Co. Marketing and Lung Health Institute dated March 28, 2017. In
effect until December 31, 2018. $50/hour for their services

 

Master
Services Agreement between Lung Health Institute, LLC and Daniel J. Edelman, Inc. dated May 9, 2018.

 

Independent
Contractor Professional Services Agreement by and between Regenerative Medicine Solutions and Russell Winwood dated March 1, 2018.

 

In
2018, RMS combined RMS Pittsburgh, RMS Nashville LLC, RMS Scottsdale, LLC, and RMS Dallas, LLC into RMS Lung Institute Management,
LLC. The previous management companies are still active and have not been dissolved but the leases have not been transferred over
in name to the new management company, RMS Lung Institute Management, LLC.

 

Per
the management agreements, RMS Lung Institute Management is paid a fee equal to what the EBIDTA would be each month for the clinics
which becomes the management fee for RMS Lung Institute Management. In Dallas and in Pittsburgh, we have been advised that the
fees should be in equal sums each month. In 2017, we amended and restated those MSA’s late in 2017 where we could estimate
every closely what the overall management fee would be annually and retroactively billed a flat fee each month for those clinics
in 2017. Due to all of the changes that have been made and will be made in the future, it will be very difficult to determine
the exact monthly management fee that should be charged to these two clinics consistently each month. For accounting purposes,
in 2018, we have been using the same methodology found in the Scottsdale and Nashville MSAs for the Dallas and Pittsburgh clinics
in which the management fees each month are equal to the net earnings of each of the respective clinics.

 

    	 

    	 

    

 

Section
4.10(a)

 

Leased
Real Property

 

Lease
Agreement by and between Healthcare Realty Services Incorporated, a Tennessee corporation, as agent for HRT of Tennessee, Inc.,
a Tennessee corporation (the “Landlord”) and Regenerative Medicine Solutions, LLC.

 

Lease
Agreement by and between NPG Venture, L.P. (Landlord) and RMS Pittsburgh, LLC (Tenant) dated April 2015.

 

Lease
Agreement by and between DTR7Y, LLC (Landlord) and RMS Scottsdale, LLC (Tenant) dated January 9, 2015, as amended by that certain
First Amendment dated May 15, 2018.

 

Standard
Form Office Lease by and between Terrance Tower Tampa, LLC (Original Landlord) and Advanced Healthcare Partners, LLC (Tenant)
dated May 7, 2013. Original Landlord assigned lease to ROC II, Fairlead Fifth Third Center, LLC (ROC II) on July 28, 2014. Assignment
of Lease by and between Tenant and Regenerative Medicine Solutions, LLC (RMS) as of May 21, 2015, whereby Tenant assigned all
interest under the Lease to RMS. First Amendment to Standard Form Office Lease by and between ROC II and RMS dated June 12, 2015,
expanding rentable square feet.

 

Office
Lease by and between SCG/CP One Glen Lakes, LLC and RMS Dallas, LLC dated December 4, 2015.

 

In
2018, RMS combined RMS Pittsburgh, RMS Nashville LLC, RMS Scottsdale, LLC, and RMS Dallas, LLC into RMS Lung Institute Management,
LLC. The previous management companies are still active and have not been dissolved but the leases have not been transferred over
in name to the new management company, RMS Lung Institute Management, LL

 

    	 

    	 

    

 

Section
4.14

 

Legal
Proceedings

 

Complaint
by Charles Dolson (Plaintiff) v. Regenerative Medicine Solutions, L.L.C., Mark Flood, DO, and Michael Perry, MD e-filed August
8, 2018 in the circuit court of the thirteenth judicial circuit in and for Hillsborough County, Florida, Civil Division.

 

Notice
from Christopher Pettus, counsel for Lung Institute patient Mr. Joseph Conti, notifying Regenerative Medicine Solutions, LLC of
the intent to file a lawsuit on behalf of Conti. Notice dated August 6, 2018.

 

Notice
from Christopher Pettus, counsel for Lung Institute patient Mr. Bill Boyuk, notifying Regenerative Medicine Solutions, LLC of
the intent to file a lawsuit on behalf of Boyuk. Notice dated August 6, 2018.

 

Notice
from Christopher Pettus, counsel for Lung Institute patient Ms. Beverly McCord, notifying Regenerative Medicine Solutions, LLC
of the intent to file a lawsuit on behalf of McCord. Notice dated August 3, 2018.

 

Notice
from Christopher Pettus, counsel for Lung Institute patient Mr. Robert Worrell, notifying Regenerative Medicine Solutions, LLC
of the intent to file a lawsuit on behalf of Worrell. Notice dated August 6, 2018.

 

Notice
from Christopher Pettus, counsel for Lung Institute patient Ms. Evelyn Taylor, notifying Regenerative Medicine Solutions, LLC
of the intent to file a lawsuit on behalf of Taylor. Notice dated August 6, 2018.

 

Notice
from Christopher Pettus, counsel for Lung Institute patient Mr. Robert Shafer, notifying Regenerative Medicine Solutions, LLC
of the intent to file a lawsuit on behalf of Shafer. Notice dated August 6, 2018.

 

Notice
from Christopher Pettus, counsel for Lung Institute patient Mr. David Piccari, notifying Regenerative Medicine Solutions, LLC
of the intent to file a lawsuit on behalf of Piccari. Notice dated August 6, 2018.

 

Notice
from Christopher Pettus, counsel for Lung Institute patient Mr. David Mansell, notifying Regenerative Medicine Solutions, LLC
of the intent to file a lawsuit on behalf of Mansell. Notice dated August 6, 2018.

 

Case
No. 8:17-cv-3113-7-23-MAP styled Tammy Rivero and Cindy Goodenow, personal representative of Howard Bennett’s estate
v. Lung Institute, LLC, filed in the U.S. District Court, Middle District of Florida, Tampa Division

 

    	 

    	 

    

 

Section
4.18(a)

 

Employees

 

RMS
Lung Institute Management:

 

 

Lung
Institute Tampa:

 

 

    	 

    	 

    

 

ACKNOWLEDGMENT

 

Each
Restricted Person acknowledges he has read this Agreement and agrees that he will take no action inconsistent with Section 6.07
of this Agreement.

 

	/s/ William
    Horne	 
	William
    Horne	 
	 	 
	/s/ James
    St. Louis	 
	James
    St. LouisEXECUTION
VERSION

 

ASSIGNMENT
AND ASSUMPTION AGREEMENT

 

This
Assignment and Assumption Agreement (this “Assignment”) is made and entered into as of January 8, 2019, by
and among Regenerative Medicine Solutions, LLC, a Delaware limited liability company (“RMS”), Lung Institute
LLC, a Delaware limited liability company (“Lung Institute”), RMS Lung Institute Management LLC, a Delaware
limited liability company (“RMS Management”), Cognitive Health Institute Tampa, LLC, a Delaware limited liability
company (“CHIT” and, together with RMS, Lung Institute, and RMS Management, collectively and individually,
the “Assignor”), and RMS Acquisition Corp., a Nevada corporation (“Assignee”).

 

RECITALS

 

WHEREAS,
Assignor and Assignee are parties to that certain Asset Purchase Agreement, dated October 15, 2018 (as amended, the “Purchase
Agreement”), pursuant to which Assignor has agreed, among other things, to assign all of its right, title and interest
in and to the Assigned Contracts and the Assumed Liabilities to Assignee.

 

WHEREAS,
Assignor desires to assign the Assigned Contracts and the Assumed Liabilities to Assignee, and Assignee desires to assume the
Assigned Contracts and Assumed Liabilities, subject to the terms and conditions of this Agreement.

 

NOW,
THEREFORE, for and in consideration of the promises and mutual agreements set forth in this Assignment and the Purchase Agreement,
and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows:

 

1.
Defined Terms. Capitalized terms used in this Assignment but not otherwise defined have the meanings given to such terms
in the Purchase Agreement.

 

2.
Assignment and Assumption. By this Assignment, Assignor assigns, transfers, conveys and delivers to Assignee all of Assignor’s
right, title and interest in and to the Assigned Contracts and the Assumed Liabilities, and Assignee accepts the foregoing assignment
of all of the rights of Assignor under the Assigned Contracts and assumes the Assumed Liabilities, in accordance with the terms
and conditions of the Assigned Contracts and Assumed Liabilities as provided in the Purchase Agreement.

 

3.
No Third Party Beneficiaries. Nothing in this Assignment shall be construed as giving any Person, other than Assignor and
Assignee and their successors and permitted assigns, any right, remedy or claim under or in respect of this Assignment or any
provision hereof.

 

4.
Enforceability and Severability. This Assignment is executed and delivered by Assignor and Assignee pursuant to the Purchase
Agreement and subject to the covenants, representations, and warranties thereof. No provisions set forth in this Assignment shall
be deemed to enlarge, alter, or amend the terms or provisions of the Purchase Agreement. If there is any conflict between the
provisions of this Assignment and the Purchase Agreement, the provisions of the Purchase Agreement shall control.

 

5.
Successors and Assigns. This Assignment shall be binding upon and shall inure to
the benefit of Assignor, Assignee and their respective heirs, executors, legal representatives, successors and permitted assigns.

 

6.
Governing Law. This Assignment shall be governed by and construed and enforced in accordance with the laws of the State
of Delaware, determined without reference to conflicts of law principles.

 

7.
Counterparts. This Assignment may be executed in one or more counterparts, all of which taken together shall constitute
one instrument. The parties agree that this Assignment may be executed and the signatures transmitted to the other party by facsimile
or similar electronic transmission. Upon such transmission and receipt by the other party, such facsimile signature shall be as
effective as an original.

 

[signature
page follows]

 

    	1

    	 

    

 

Assignor
and Assignee have caused this Assignment to be executed as of the day and year first above written.

 

	 	ASSIGNOR:
	 	 
	 	REGENERATIVE MEDICINE SOLUTIONS, LLC
	 	a Delaware limited liability company
	 	 
	 	By:	/s/ James
    St. Louis
	 	 	James
    St. Louis
	 	Its:	CEO
    and Manager
	 	 
	 	LUNG INSTITUTE, LLC
	 	 
	 	By:	/s/ James
    St. Louis
	 	Name:	James
    St. Louis
	 	Title:	CEO
    and Manager
	 	 
	 	RMS LUNG INSTITUTE MANAGEMENT LLC
	 	 
	 	By:	/s/ James
    St. Louis
	 	Name:	James
    St. Louis
	 	Title:	CEO
    and Manager
	 	 
	 	COGNITIVE HEALTH INSTITUTE TAMPA, LLC
	 	 
	 	By:	/s/ James
    St. Louis
	 	Name:	James
    St. Louis
	 	Title:	CEO
    and Manager

 

[Signature
Page to Assignment and Assumption Agreement]

 

    	 	 	 

     

    

 

	 	ASSIGNEE:
	 	 	 
	 	RMS ACQUISITION CORP.
	 	a Nevada corporation
	 	 	 
	 	By:	/s/ Charles
    Farrahar
	 	Name:	Charles
    Farrahar
	 	Title:	Chief
    Executive Officer

 

[Signature
Page to Assignment and Assumption Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]